Renal amyloidosis is a serious kidney disease in which abnormally folded proteins, called amyloid fibrils, accumulate in kidney tissue and gradually destroy its ability to filter blood. The hallmark presentation is heavy protein loss in the urine, often progressing to full kidney failure if the underlying cause is not controlled. Several distinct proteins can misfold and deposit in the kidneys, and identifying which one is responsible is critical because the treatment for each type differs dramatically.
How Amyloid Fibrils End Up in the Kidney
Amyloid formation starts with a precursor protein that misfolds. These misfolded copies then stick together in a highly ordered fashion, first forming thin strands called protofilaments that combine into the characteristic rigid fibrils seen under a microscope.1PubMed. Amyloidosis-associated kidney disease The fibrils are remarkably stable and resist the body’s normal cleanup mechanisms, so once they begin accumulating in an organ, they tend to stay and grow unless the supply of the precursor protein is shut off.
In the kidney, amyloid can deposit in three main compartments: the glomeruli (the tiny filtering units), the blood vessels, and the tissue between the tubules. A study examining the distribution across hundreds of biopsies found that roughly 85% of cases showed a predominantly glomerular pattern, about 9% were mainly vascular, and 6% were primarily in the space between tubules.2PubMed. Renal amyloidosis revisited: amyloid distribution, dynamics and biochemical type Within the glomeruli, the deposits typically start in small patches and then spread until they replace much of the normal filtering structure. That progression explains why proteinuria worsens over time and eventually becomes massive.
The Major Types of Renal Amyloidosis
At least a dozen different proteins can form amyloid in the kidney, but a handful account for the vast majority of cases. The type matters enormously because it dictates what treatment you receive, what your prognosis looks like, and how aggressively clinicians need to act.
AL Amyloidosis
AL (immunoglobulin light chain) amyloidosis is the most commonly diagnosed form in developed countries. It arises when a small, abnormal population of plasma cells in the bone marrow produces excess light chain proteins that misfold and deposit as amyloid. The kidneys are one of the most frequently affected organs, alongside the heart. Renal involvement typically shows up as heavy proteinuria, and many patients present with full nephrotic syndrome, meaning they lose enough protein in their urine to cause swelling, low blood albumin, and high cholesterol.3PubMed. Renal Amyloidosis: Presentation, Diagnosis, and Management Because the underlying problem is a bone marrow disorder, treatment targets those abnormal plasma cells, and the speed at which kidney function responds depends heavily on how quickly the light chain production can be suppressed.
AA Amyloidosis
AA amyloidosis, sometimes called secondary amyloidosis, results from chronic inflammation. Conditions such as rheumatoid arthritis, periodic fever syndromes, and long-standing infections drive the liver to produce large amounts of serum amyloid A (SAA) protein, fragments of which can misfold into amyloid fibrils.4PubMed Central. Serum Amyloid A Protein-Associated Kidney Disease: Presentation, Diagnosis, and Management Animal research has shown that the circulating SAA concentration is the key driver: high levels lead to rapid amyloid deposition, while even modest overproduction over a long period can “prime” tissues for explosive amyloid accumulation once SAA rises further.5PubMed Central. Pathogenetic mechanisms of amyloid A amyloidosis
A landmark natural history study of AA amyloidosis found that outcomes track tightly with how well SAA is controlled. Patients whose median SAA concentration stayed below 10 mg per liter saw amyloid deposits actually regress in 60% of cases, while those with concentrations above 155 mg per liter had a risk of death roughly 18 times higher than those with the lowest levels.6PubMed. Natural history and outcome in systemic AA amyloidosis The practical message is clear: controlling the inflammatory disease that keeps SAA elevated is the single most important thing you can do for kidney outcomes.
ALECT2 Amyloidosis
ALECT2 amyloidosis, caused by the protein leukocyte chemotactic factor 2, is a relative newcomer to clinical awareness. It tends to affect older adults, presenting with slowly progressive kidney disease and relatively mild protein loss in the urine, which makes it easy to miss. Unlike AL amyloidosis, nephrotic-range proteinuria is uncommon, and the amyloid deposits prefer the space between tubules and the blood vessels rather than the glomeruli.7PubMed Central. Leukocyte Chemotactic Factor 2 Amyloidosis (LECT‐2) Amyloidosis Case Report and Review of the Current Literature Because of its subtle presentation, ALECT2 is probably underdiagnosed, and many cases are only caught on biopsy done for other reasons. There is currently no specific therapy; management is supportive.
Hereditary Transthyretin Amyloidosis
Hereditary transthyretin (ATTRv) amyloidosis is best known for causing neuropathy and heart disease, but the kidneys are not spared. In a cohort of over 100 patients with symptomatic ATTRv, about 16% had chronic kidney disease at diagnosis, and that proportion climbed to roughly 30% at the last follow-up. A small but meaningful fraction developed end-stage kidney failure requiring dialysis.8PubMed Central. Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients Kidney involvement in ATTRv is easily overshadowed by the more dramatic cardiac and neurological symptoms, so clinicians caring for these patients need to monitor kidney function proactively.
What Renal Amyloidosis Looks and Feels Like
The classic presentation is proteinuria that progresses from mild to severe. Many patients first notice foamy urine or swelling in their legs and around their eyes, the telltale signs of nephrotic syndrome. As the disease advances, kidney function declines, and without treatment, end-stage kidney failure is a real possibility.9PubMed Central. Renal amyloidosis: a new time for a complete diagnosis How fast this happens varies by type: AL amyloidosis can progress within months, while ALECT2 may smolder for years.
One complication that is underappreciated is renal vein thrombosis, where a blood clot forms in the vein draining the kidney. Nephrotic syndrome creates a hypercoagulable state because the kidneys leak out proteins that normally prevent clotting. Case reports have documented acute kidney failure triggered by bilateral renal vein clots in patients with secondary amyloidosis, sometimes with fatal outcomes.10PubMed. Case report: acute renal vein thrombosis in patients with spinal cord injury and secondary amyloidosis If a patient with known amyloidosis experiences a sudden worsening in kidney function or flank pain, clotting should be on the differential.
Beyond the kidneys, systemic amyloidosis often involves other organs simultaneously. AL amyloidosis frequently affects the heart, which makes treatment more urgent and more complex. AA amyloidosis can involve the gut, liver, and spleen. Because multi-organ involvement is common, renal amyloidosis is rarely a kidney-only problem, and the overall prognosis depends on which other organs are damaged and how severely.
How Renal Amyloidosis Is Diagnosed
Diagnosis requires a tissue biopsy, and for renal amyloidosis, a kidney biopsy is the gold standard. The first step in the pathology lab is a Congo red stain: amyloid deposits absorb the dye and produce a characteristic apple-green glow (birefringence) when viewed under polarized light.11PubMed. An evaluation of Congo red fluorescence for the diagnosis of amyloidosis This technique has been the workhorse of amyloid detection since the early 20th century, but it has limitations: small deposits can be missed, and the stain itself does not reveal which protein made the amyloid.
Identifying the amyloid type is the step that truly matters for treatment, and this is where the field has been transformed by mass spectrometry. Laser microdissection of the amyloid deposit followed by proteomic analysis directly identifies the proteins present, revealing whether the fibrils are made of light chains, serum amyloid A, transthyretin, LECT2, or one of the rarer culprits.12PubMed Central. Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis Before mass spectrometry became widely available, typing relied on immunohistochemistry, which uses antibodies to detect specific proteins on the tissue slide. Immunohistochemistry works reasonably well for AA amyloidosis but is notoriously unreliable for AL, because the antibodies can cross-react or fail to bind the distorted light chain within the fibril. Mass spectrometry has largely resolved these ambiguities and is now considered the definitive typing method at specialized centers.
Imaging is playing a growing role in monitoring disease burden without repeated biopsies. SAP scintigraphy, available mainly in a few European centers, uses a radiolabeled version of serum amyloid P component to visualize amyloid deposits in the liver, spleen, kidneys, and other organs. Researchers have also explored PET tracers originally developed for brain amyloid in Alzheimer’s disease, though these are still largely investigational for systemic amyloidosis. In parallel, heparin-binding peptide tracers have shown promise in animal models, binding to amyloid deposits in multiple organs including the kidney with enough avidity to appear on imaging up to 24 hours after injection.13PubMed Central. In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides
Distinguishing Amyloid From Look-Alikes
Under the microscope, amyloid is not the only thing that forms organized deposits in the kidney. Fibrillary glomerulonephritis, immunotactoid glomerulopathy, and cryoglobulinemic glomerulonephritis can all produce fibrillar or structured deposits that might initially be confused with amyloid. The key differentiator is the Congo red stain: true amyloid is Congo red-positive with apple-green birefringence, while the look-alikes are negative. Electron microscopy helps further, since amyloid fibrils are thinner and more randomly arranged than the microtubular structures seen in immunotactoid disease. When there is any doubt, mass spectrometry on the dissected tissue settles the question definitively.
Treating AL Amyloidosis in the Kidney
Because AL amyloidosis is driven by an abnormal clone of plasma cells, treatment borrows heavily from the playbook used for related blood cancers. The goal is to eliminate the clone and stop the supply of misfolded light chains, which allows the kidneys a chance to recover. How deeply you suppress those light chains matters immensely: patients who achieve what hematologists call a complete response or very good partial response fare far better in the long run.
The ANDROMEDA trial established the combination of daratumumab (an antibody that targets plasma cells) with the chemotherapy backbone of cyclophosphamide, bortezomib, and dexamethasone as the new standard of care. At six months, patients in the daratumumab group had a renal response rate more than double that of the control group receiving chemotherapy alone, roughly 53% versus 24%.14PubMed. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis Earlier safety run-in data from the same trial showed that kidney responses continued to deepen over time, reaching about two-thirds of evaluable patients by 12 months.15Blood. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA In relapsed patients who had already failed prior therapy, daratumumab as a single agent still produced kidney responses in about two-thirds of those with renal involvement.16PubMed Central. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study
Organ response, not just blood-test improvement, is the ultimate yardstick. A study tracking over 300 AL patients who achieved normal free light chain ratios after treatment found that roughly 80% of survivors had a measurable organ response within a year. Those who achieved that organ response early had better long-term survival than those who did not, even if both groups had identical blood-test results.17PubMed Central. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis In practical terms, this means that after starting treatment, clinicians watch proteinuria and kidney function closely for signs that the kidneys are actually recovering, not just that the underlying blood disorder is controlled.
Treating AA Amyloidosis in the Kidney
For AA amyloidosis, the treatment target is the inflammatory disease that keeps SAA production elevated. If you can bring SAA levels down and keep them there, kidney function can stabilize and sometimes improve. The choice of anti-inflammatory therapy depends on the underlying condition. In rheumatoid arthritis, biologic drugs have changed the landscape. TNF inhibitors, the T-cell modulator abatacept, rituximab, and JAK inhibitors have all shown the ability to slow or prevent organ damage in AA amyloidosis.18PubMed Central. Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: Case report and review of literature
Among these, IL-6 inhibitors such as tocilizumab stand out. IL-6 is the main cytokine that drives the liver to produce SAA, so blocking it can normalize SAA levels in most patients, provided drug concentrations remain adequate. This makes IL-6 blockade an attractive strategy for AA amyloidosis regardless of the specific inflammatory disease driving it.19Modern Rheumatology. AA amyloidosis – Benefits and prospects of IL-6 inhibitors TNF inhibitors also reduce SAA but do not always bring it all the way down to normal, which matters because even modestly elevated SAA levels are associated with continued amyloid deposition and worse kidney outcomes, as the natural history data discussed earlier demonstrate.
Kidney Transplantation
When kidneys fail despite treatment, transplantation is an option, but the specter of amyloid recurring in the new kidney is a legitimate concern. For AL amyloidosis, the data are encouraging if the blood disorder is well controlled. A large international study of 237 AL patients who received a kidney transplant found a median overall survival of about 8.6 years from transplantation. Among those who had achieved a complete or very good partial response before the transplant, median graft survival was roughly 8.3 years, and the rate of amyloid recurring in the graft was 16%. Patients with less well-controlled disease had shorter graft survival (about 5.7 years) and a recurrence rate more than double that figure.20PubMed Central. Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group Even among those who relapsed hematologically after transplant, timely treatment prevented graft loss in the large majority.
A single-center Mayo Clinic analysis painted a similarly favorable picture, with death-censored graft survival reaching about 96% at five years. Amyloid recurrence was seen in roughly a fifth of patients, but the authors emphasized that good hematologic response before or after transplant was the key to acceptable outcomes.21PubMed Central. Long-term outcomes of kidney transplantation in patients with AL amyloidosis from The Mayo Clinic The overall takeaway is that kidney transplantation should not be reflexively ruled out for amyloidosis patients, but candidate selection matters enormously. A transplant done while the precursor protein is still being produced in large amounts is unlikely to last.
Therapies on the Horizon
Current treatments all work “upstream,” trying to stop the production of the precursor protein. A fundamentally different strategy would be to remove amyloid deposits that have already formed. An antibody targeting serum amyloid P component (SAP), a protein that coats virtually all amyloid fibrils, was tested in a proof-of-concept trial. After depleting circulating SAP with a small-molecule drug, patients received the anti-SAP antibody, and those who received an adequate dose showed reductions in amyloid burden across multiple organs, including the kidney.22PubMed. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component The results were encouraging but the program has faced development setbacks, and no amyloid-clearing antibody is approved for clinical use yet.
A newer approach involves an antibody-peptide fusion called AT-02 that binds amyloid fibrils across all types and flags them for immune destruction. In laboratory experiments, AT-02 overcame a “don’t eat me” signal that normally shields amyloid deposits from being cleared by immune cells, enhancing phagocytosis by macrophages and monocytes.23npj drug discovery. The antibody-peptide fusion protein, AT-02, is an effective opsonin with pan-amyloid reactivity If this translates to humans, a pan-amyloid opsonin could theoretically benefit patients regardless of which protein formed their deposits, sidestepping the need for type-specific treatment of the deposits themselves.
For hereditary transthyretin amyloidosis specifically, gene silencing therapies using antisense oligonucleotides or small interfering RNA have transformed the treatment of neuropathy and cardiomyopathy. These drugs reduce the liver’s production of transthyretin by over 80%, and there is interest in extending their use to patients who develop progressive kidney disease or who have had a liver transplant and continue to accumulate amyloid from wild-type transthyretin produced by the new graft.24Amyloid. TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients Whether the kidney benefits seen in cardiac and neurological trials will hold up in dedicated renal studies remains to be seen, but the mechanistic rationale is strong.
Why Accurate Typing Still Trips Up Clinicians
One of the persistent challenges in renal amyloidosis is mistyping. If a biopsy confirms amyloid but the type is wrongly identified, the patient can receive entirely the wrong treatment. A person with ALECT2 amyloidosis mistakenly labeled as having AL might undergo aggressive chemotherapy aimed at plasma cells, which would carry real toxicity risks with zero benefit. Conversely, genuine AL amyloidosis misidentified as AA might be treated with anti-inflammatory drugs while the malignant clone continues to pump out toxic light chains.
The root of the problem is over-reliance on clinical context and immunohistochemistry rather than definitive molecular testing. If a patient has rheumatoid arthritis and their biopsy shows amyloid, the temptation to call it AA without further testing is strong. But studies using mass spectrometry on cases originally typed by immunohistochemistry have uncovered a meaningful rate of discordance, with cases reclassified to different amyloid types. The lesson is that every case of renal amyloidosis should ideally have mass spectrometry-based typing, especially before committing to treatment with significant side effects. Access to this technology is still limited to larger academic centers, but it is expanding, and awareness of its importance has grown considerably over the past decade.